关闭
浙大通行证登录

蒋晞

性别:女
职称:百人计划研究员(自然科学B类)
单位:医学院
电子信箱:xjiang@zju.edu.cn

最近访问您主页的用户IP地址

序号 访问时间 IP地址 所在区域

序号 时间段 URL地址

个人简介

  蒋晞博士,浙江大学医学院研究员、博士生导师。2017年入选国家“千人计划”青年项目、浙江大学“百人计划”。课题组主要研究肿瘤,特别是白血病的表观遗传学调节机制,以及针对表观遗传学机制的临床转化应用。研究成果和代表性论文如下:1阐明一系列微核糖核酸在白血病中的作用机制,采用靶向特异性纳米载体运输抑癌微核糖核酸治疗白血病 Nat Commun, 2016; Cancer Res, 2016; Cancer Cell, 2012; Proc Natl Acad Sci, 2012);2揭示TET1介导的DNA 5-羟甲基胞嘧啶(5-hydroxymethylcytosine; 5hmC)修饰在白血病中的作用和机制,通过高通量小分子化合物筛选找寻TET1表达抑制剂治疗白血病(Nat Commun, 2017; Nat Commun, 2016; Proc Natl Acad Sci, 2013);3揭示RNA N6-甲基腺苷(N6-Methyladenosine; m6A)修饰在造血分化和白血病中的作用机制以及治疗应用(Cell, 2018; Cell Stem Cell, 2018; Cancer Cell, 2017)。

 

研究方向

  课题组致力于白血病的靶向治疗,主要研究方向为白血病表观遗传学调节网络,以及针对表观遗传学机制的临床转化应用。课题组的长期目标是通过与临床、制药的紧密合作,将基础研究发现的新疗法运用于临床,开发抗肿瘤靶向新药。具体方向包括

1、研究DNARNA 修饰在白血病化疗反应中的作用和调节机制;

2、探寻针对致癌DNARNA调控因子最佳靶位点的小分子拮抗剂;

3、筛选直接或间接作用于DNARNA修饰、且具潜在AML治疗作用的小分子化合物。

 

教育工作经历

2000-2005 复旦大学医学院 学士

2005-2010 复旦大学医学院 博士 (导师:马兰教授)

2010-2014 美国芝加哥大学(University of Chicago 博士后 (导师:美国科学院院士Janet D. Rowley教授和陈建军教授)

2015-2017 美国辛辛那提大学(University of Cincinnati)助理教授(研究型)(Assistant Professor-Research

2017-2018 美国希望城国家医疗中心(Beckman Research Institute of City of Hope)研究型助理教授(Assistant Research Professor, Step III

2018-  浙江大学医学院 研究员、博士生导师

 

奖励荣誉

国家“千人计划”青年项目 2017

美国血液病学会年会杰出摘要奖 Abstract Achievement Award for the American Society of Hematology (ASH) Annual Meeting)(20122014

美国芝加哥大学肿瘤生物学委员会博士后奖学金 The Committee on Cancer Biology (CCB) postdoctoral fellowship, the University of Chicago 2013

全美第8届肿瘤生物学联合会年会优秀报告奖 Top 3 Abstract Award for 8th Annual Meeting of the Cancer Biology Training Consortium 2012

美国加百列天使肿瘤研究奖励基金(The Gabrielle's Angel Foundation Award 2012

上海市普通高校优秀博士毕业生 2010

 

主持的相关项目

1. 美国芝加哥大学肿瘤生物学委员会博士后研究基金(The Committee on Cancer Biology (CCB) Postdoctoral Fellowship):携带miR-150的纳米药物治疗MLL染色体重构的AML的疗效评估 Evaluation of Therapeutic Potential of miR-150 Mimics Carried by Nano-particles in Treating MLL-Rearranged Leukemia2012-2014)(主持人)

2. 美国加百列天使肿瘤研究基金(Gabrielle's Angel Foundation for Cancer Research):miR-495AML中作用和调节机制的研究 The Function and Regulatory Mechanism of miR-495 in Acute Myeloid Leukemia (AML)2012-2013)(主持人)

3. 复旦大学研究生创新基金:G蛋白偶联受体激酶在胚胎发育中作用的研究(2009-2010)(主持人)

4. 美国国立卫生研究院/国家肿瘤研究院(NIH/NCI) R01CA211614:应用TET1信号通路抑制剂靶向性治疗AML的研究 Targeting TET1 Signaling to Treat Acute Myeloid Leukemia2017-2021)(共同主持)

5. 美国国立卫生研究院/国家肿瘤研究院(NIH/NCI) R01CA182528:靶向性针对miR-150治疗AML的研究 Potential Therapeutic Implications of Targeting miR-150 in Acute Myeloid Leukemia2014-2018)(共同主持)

6. 美国白血病淋巴瘤学会转化研究基金(Leukemia & Lymphoma Society (LLS) Translational Research Grant):靶向性针对miR-22治疗MLL染色体重构的AML的研究 Therapeutic Potential of miR-22 in Treating MLL-Rearranged Leukemias2013-2016)(共同主持)

7. 美国Alex's Lemonade Stand 基金会创新基金(Alex's Lemonade Stand Foundation Innovation Award):MicroRNA纳米药物治疗MLL重构的小儿急性白血病的研究 Development of MicroRNA-Nanoparticles to Treat Childhood Acute Leukemia Carrying MLL Rearrangements2013-2015)(共同主持)

 

代表性论文*并列一作; #通讯作者/并列通讯作者)

(1) Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki A, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J. (2018) R-2HG exhibits anti-tumor activity by targeting FTO/MYC signaling. Cell. 11; 90-105. PMID: 29249359. IF=30.4

(2) Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore L, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 22; 191-205. PMID: 29290617. IF=22.4

(3) Huang H, Weng H, Sun W, Qin X, Shi H, Zhao BS, Mesquita A, Yuan CL, Hu YC, Hüttelmaier S, Strong J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Qu L, Guan JL, He C, Yang J, Chen J. Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability. Nat Cell Biol. 20 285-295. PMID: 29476152. IF=20.1

(4) Jiang Xi#, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J. (2017) Targeted inhibition of TET1 transcription as a potent therapeutic strategy for acute myeloid leukemia. Nat Commun. 13; 2099. PMID: 29235481. IF=12.1

(5) Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, Qin X, Jin J, Chen J, Jiang Xi#. (2017) ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep. 12; 1853. PMID: 28500307. IF=4.3

(6) Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. (2017) FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 31; 127-141. PMID: 28017614. IF=27.4

(7) Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J. (2016) miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 26; 11452. PMID: 27116251. IF=12.1

(8) Jiang X#, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J. (2016) Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 76; 4470-4480. PMID: 27280396. IF=9.3

(9) Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J. (2016) PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res. 76, 619-629. PMID: 26747896. IF=9.3

(10) Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. (2016) Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 372, 157-165. PMID: 26791235. IF=6.4

(11) Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. (2015) Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 126, 2005-2015. PMID: 26361793. IF=13.2

(12) He Y, Jiang X and Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 33, 3887-93. PMCID: Pending. IF=8.5

(13) Huang H*, Jiang X*, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C and Chen J. (2013) TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 110, 11994-11999. PMCID: PMC3718141. IF=9.7

(14) Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews J, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C and Chen J. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 16, 524-535. PMCID: PMC3480215. IF=27.4

(15) Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD and Chen J. (2012) miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 20, 19397-19402. PMCID: PMC3511140. IF=9.7

(16) Li Z*, Huang H*, Li Y*, Jiang X*, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD and Chen J. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119, 2314-2324. PMCID: PMC3311258. IF=13.2

(17) Jiang X and Chen J. (2012) miR-150: targeting MLL leukemia. Oncotarget. 3, 1268-1269. PMCID: PMC3717789. IF=5.2

(18) Jiang X, Yang P and Ma L. (2009) Kinase activity-independent regulation of Cyclin pathway by GRK2 Is essential for zebrafish early development. Proc Natl Acad Sci USA. 106, 10183-10188. PMCID: PMC2700943. IF=9.7


专利成果

(1) Jiang X, Chen J. TET1 transcriptional inhibitors as a therapeutic strategy for acute myeloid leukemia (AML). (使用TET1表达抑制剂治疗急性髓细胞性白血病) Serial No. 62/490,184. Submitted on 4/21/2017. Pending.

(2) Chen J, Jiang X. Anti-tumor role of miR-22 with therapeutic potential in acute myeloid leukemia. 靶向针对miR-22的急性髓细胞性白血病治疗)Serial No. 62/416,829. Submitted on 11/3/2016. Pending.

(3) Chen J, Jiang X, Hong S, Li Z. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. (FLT3配体介导的miR-150纳米药物的靶向治疗) Serial No. 62/349,707. Submitted on 6/14/2016. Pending.

 

学术交流

五十九届美国血液病学会年会,美国亚特兰大,2017

西湖论坛-第六届白血病淋巴瘤峰会,中国杭州,2016

全美第八届肿瘤生物学联合会年会,美国圣地亚哥,2012

第八届中国神经科学双年会,中国广州,2009

 

本课题组正在积极招收博士后、技术员和研究生,欢迎加盟!


联系方式

电子信箱:xjiang@zju.edu.cn